Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate(TM) Trial

PURPOSE: The first report from the open-label substudy of the phase III iNNOVATE study (PCYC-1127; NCT02165397) demonstrated that single-agent ibrutinib was efficacious and well tolerated in patients with heavily pretreated, rituximab-refractory Waldenström macroglobulinemia. Results from the final...

Descripción completa

Detalles Bibliográficos
Autores principales: Trotman, Judith, Buske, Christian, Tedeschi, Alessandra, Matous, Jeffrey V., MacDonald, David, Tam, Constantine S., Tournilhac, Olivier, Ma, Shuo, Treon, Steven P., Oriol, Albert, Ping, Jerry, Briso, Eva M., Arango-Hisijara, Israel, Dimopoulos, Meletios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401517/
https://www.ncbi.nlm.nih.gov/pubmed/34380643
http://dx.doi.org/10.1158/1078-0432.CCR-21-1497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9401517/
https://www.ncbi.nlm.nih.gov/pubmed/34380643
http://dx.doi.org/10.1158/1078-0432.CCR-21-1497

Ejemplares similares